keyword
MENU ▼
Read by QxMD icon Read
search

Lurasidone

keyword
https://www.readbyqxmd.com/read/28927482/treating-depressive-episodes-or-symptoms-in-patients-with-schizophrenia
#1
Geeske van Rooijen, Jentien Marloes Vermeulen, Henricus Gerardus Ruhé, Lieuwe de Haan
Depressive episodes or symptoms occur frequently in patients with schizophrenia and may have far-reaching consequences. Despite the high prevalence rate and clinical relevance of this comorbidity, knowledge about treatment options is still limited. The aim of this review is to provide an overview of the literature concerning treatment options for depressive episodes or symptoms in schizophrenia. Based on the current evidence, we present a stepwise treatment approach. The first step is to evaluate the current antipsychotic treatment of psychotic symptoms and consider lowering the dosage, since increased blockade of the dopamine D2 receptors may be associated with a worse subjective sense of well-being and dysphoria...
September 20, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/28902525/lurasidone-efficacy-and-safety-in-the-treatment-of-psychotic-and-mood-disorders
#2
Maurizio Pompili, Claudio Verzura, Giada Trovini, Andrea Buscajoni, Giulia Falcone, Stefano Naim, Adele Nardella, Serena Sorice, Ross J Baldessarini, Paolo Girardi
Lurasidone ([3aR,4S,7R,7aS]-2-[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1yl-methyl] cyclohexylmethyl]-hexahydro-4,7-methano-2H-isoindole-1,3-dione hydrochloride; Latuda® [LRSD]) is a novel benzisothiazole, second-generation antipsychotic drug developed by Dainippon Sumitomo Pharma Corporation in Japan. Similar to other atypical antipsychotics it has a distinctive pharmacodynamic profile, Areas covered: This review updates reported research findings on the efficacy, safety and tolerability of LRSD for treatment of psychotic and major affective disorders, with meta-analyses...
September 13, 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/28807142/efficacy-of-lurasidone-in-the-treatment-of-agitation-a-post-hoc-analysis-of-five-short-term-studies-in-acutely-ill-patients-with-schizophrenia
#3
Michael H Allen, Leslie Citrome, Andrei Pikalov, Jay Hsu, Antony Loebel
OBJECTIVE: This post hoc analysis evaluated the effect of lurasidone on agitation in acutely ill patients with schizophrenia. METHOD: Patient-level data were pooled from five 6-week, randomized, double-blind, placebo-controlled studies of fixed-dose, once-daily, oral lurasidone (40, 80, 120, or 160 mg/d). Agitation was assessed with the Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) score, utilizing a mixed model for repeated measurement analysis...
July 2017: General Hospital Psychiatry
https://www.readbyqxmd.com/read/28806387/lurasidone-associated-neuroleptic-malignant-syndrome
#4
Mei Lee, Dorian Marshall, Sahoo Saddichha
No abstract text is available yet for this article.
October 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28796415/white-matter-tract-integrity-is-associated-with-antidepressant-response-to-lurasidone-in-bipolar-depression
#5
Martin J Lan, Harry Rubin-Falcone, Fatima Motiwala, Ying Chen, Jonathan W Stewart, David J Hellerstein, J John Mann, Patrick J McGrath
OBJECTIVES: Patients with bipolar disorder spend the most time in the depressed phase, and that phase is associated with the most morbidity and mortality. Treatment of bipolar depression lacks a test to determine who will respond to treatment. White matter disruptions have been found in bipolar disorder. Previous reports suggest that white matter disruptions may be associated with resistance to antidepressant medication, but this has never been investigated in a prospective study using a Food and Drug Administration (FDA)-approved medication...
August 10, 2017: Bipolar Disorders
https://www.readbyqxmd.com/read/28740811/change-in-daytime-sleepiness-and-cognitive-function-in-a-6-month-double-blind-study-of-lurasidone-and-quetiapine-xr-in-patients-with-schizophrenia
#6
Philip D Harvey, Cynthia O Siu, Antony D Loebel
Daytime sleepiness is a commonly reported adverse effect associated with psychotropic agents that may impair cognitive performance and functioning. The objective of this post-hoc analysis was to evaluate the long-term effects of lurasidone and quetiapine XR on daytime sleepiness and neurocognitive performance during a 6-month, double-blind continuation study, in subjects who completed an initial 6-week, randomized, placebo-controlled trial comparing these agents. Daytime sleepiness, cognitive performance, and health-related quality of life were assessed with the Epworth Sleepiness Scale (ESS), CogState computerized battery, and the Quality of Well-Being (QWB-SA) Scale, respectively...
September 2016: Schizophrenia Research. Cognition
https://www.readbyqxmd.com/read/28738099/a-case-series-on-the-effectiveness-of-lurasidone-in-patients-with-stuttering
#7
Janet Charoensook, Gerald A Maguire
BACKGROUND: The prevalence of stuttering is approximately 1% of the population, affecting an estimated 3 million individuals in the United States. The dopamine hypothesis of stuttering explains that abnormally increased cerebral dopamine affects the balanced levels that maintain the basal ganglia circuits, which helps with timing cues in initiating speech. This is especially significant when considering treatment strategies. We report a reduction in stuttering with lurasidone, a potent D2 receptor antagonist with a relatively favorable adverse effects profile...
August 2017: Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists
https://www.readbyqxmd.com/read/28727644/cariprazine-specificity-profile-in-the-treatment-of-acute-schizophrenia-a-meta-analysis-and-meta-regression-of-randomized-controlled-trials
#8
Filippo Corponi, Alessandro Serretti, Stuart Montgomery, Chiara Fabbri
Cariprazine is a new dopamine D2 and D3 receptor partial agonist antipsychotic. Meta-analytic evidence of efficacy in acute schizophrenia and specific groups of patients is lacking. We carried out a meta-analysis in patients with acute schizophrenia to evaluate the efficacy of cariprazine over placebo and active comparators in overall symptoms, positive and negative symptoms and quality of life. Low and high (≥6 mg/day) doses were tested separately. The possible effect of clinical-demographic modulators was also tested...
July 19, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28721057/safety-tolerability-and-risks-associated-with-first-and-second-generation-antipsychotics-a-state-of-the-art-clinical-review
#9
REVIEW
Marco Solmi, Andrea Murru, Isabella Pacchiarotti, Juan Undurraga, Nicola Veronese, Michele Fornaro, Brendon Stubbs, Francesco Monaco, Eduard Vieta, Mary V Seeman, Christoph U Correll, André F Carvalho
Since the discovery of chlorpromazine (CPZ) in 1952, first-generation antipsychotics (FGAs) have revolutionized psychiatric care in terms of facilitating discharge from hospital and enabling large numbers of patients with severe mental illness (SMI) to be treated in the community. Second-generation antipsychotics (SGAs) ushered in a progressive shift from the paternalistic management of SMI symptoms to a patient-centered approach, which emphasized targets important to patients - psychosocial functioning, quality of life, and recovery...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/28695535/single-and-multiple-dose-pharmacokinetics-safety-and-tolerability-of-lurasidone-in-healthy-chinese-subjects
#10
Chaoying Hu, Yijun Wang, Rong Song, Chen Yu, Xiaoyan Luo, Jingying Jia
BACKGROUND AND OBJECTIVE: The pharmacokinetics of lurasidone have been studied in healthy Japanese and Caucasian subjects, but not in Chinese subjects. The objective of this study was to evaluate the pharmacokinetics, safety, and tolerability of oral lurasidone in healthy Chinese subjects. METHODS: This single-center, randomized, parallel-group, placebo-controlled, and double-blind study evaluated the pharmacokinetics, safety, and tolerability of oral lurasidone administered as a single dose (20, 40, and 80 mg) and multiple doses for 5 days (40 mg administered once daily) in healthy Chinese subjects...
July 10, 2017: Clinical Drug Investigation
https://www.readbyqxmd.com/read/28689688/lurasidone-in-combination-with-lithium-or-valproate-for-the-maintenance-treatment-of-bipolar-i-disorder
#11
Joseph R Calabrese, Andrei Pikalov, Caroline Streicher, Josephine Cucchiaro, Yongcai Mao, Antony Loebel
Lurasidone (DS-RAn) has demonstrated efficacy in the acute treatment of bipolar depression, both as monotherapy, and as combination therapy with lithium or valproate. To evaluate the recurrence prevention efficacy of lurasidone for the maintenance treatment of bipolar I disorder, patients received up to 20 weeks of open-label lurasidone (20-80mg/d) combined with lithium or valproate during an initial stabilization phase. A total of 496 patients met stabilization criteria and were randomized to 28 weeks of double-blind treatment with lurasidone (20-80mg/d) or placebo, in combination with lithium or valproate...
July 6, 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28685626/lurasidone-for-the-treatment-of-irritability-and-anger-in-autism-spectrum-disorders
#12
REVIEW
Lynn McClellan, Kelli C Dominick, Ernest V Pedapati, Logan K Wink, Craig A Erickson
Autism Spectrum Disorder (ASD) is a heterogeneous neurodevelopmental disorder characterized by deficits in social interaction and communication as well as restricted patterns of behaviors and interests. Irritability marked by tantrums, self-injury and aggression occurs frequently in youth with ASD, causing significant parent and caregiver distress. Atypical antipsychotics have been the most studied drug class targeting irritability in ASD. Risperidone and aripiprazole are Food and Drug Administration (FDA)-approved atypical antipsychotics for treatment of irritability in youth with ASD...
August 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28590601/patient-characteristics-associated-with-use-of-lurasidone-versus-other-atypical-antipsychotics-in-patients-with-bipolar-disorder-analysis-from-a-claims-database-in-the-united-states
#13
Mauricio Tohen, Daisy Ng-Mak, Krithika Rajagopalan, Rachel Halpern, Chien-Chia Chuang, Antony Loebel
Objective: To compare patient characteristics, medical comorbidities, health care utilization, and health care costs among patients with bipolar disorder who initiated lurasidone versus other atypical antipsychotics in usual clinical practice. Methods: A retrospective analysis of administrative claims data was conducted using the US Optum Research Database (December 30, 2012, through February 27, 2014). Adult, commercially insured patients with bipolar disorder with an atypical antipsychotic prescription between June 28, 2013, and November 30, 2013, were included...
June 1, 2017: Primary Care Companion to CNS Disorders
https://www.readbyqxmd.com/read/28579725/cost-savings-from-an-antipsychotic-tablet-splitting-program
#14
Heather Carey, Mark Fondriest
BACKGROUND: Newer atypical antipsychotics such as aripiprazole (Abilify, Otsuka) and lurasidone (Latuda, Sunovion) have favorable safety and efficacy profiles, but their use is limited by high cost. University Hospitals Richmond Medical Center initiated an antipsychotic tablet-splitting program in August 2015 to counter the costs based on the identical pricing structure of aripiprazole and lurasidone doses. METHODS: A retrospective chart review was completed for all patients dispensed aripiprazole or lurasidone oral tablets from May 1, 2015, through December 31, 2015, to evaluate the potential cost-savings for our facility...
June 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28573138/lurasidone-in-the-treatment-of-bipolar-depression-systematic-review-of-systematic-reviews
#15
REVIEW
Michele Fornaro, Domenico De Berardis, Giampaolo Perna, Marco Solmi, Nicola Veronese, Laura Orsolini, Elisabetta Filomena Buonaguro, Felice Iasevoli, Cristiano André Köhler, André Ferrer Carvalho, Andrea de Bartolomeis
INTRODUCTION: A burgeoning number of systematic reviews considering lurasidone in the treatment of bipolar depression have occurred since its Food and Drug Administration extended approval in 2013. While a paucity of available quantitative evidence still precludes preliminary meta-analysis on the matter, the present quality assessment of systematic review of systematic reviews, nonetheless, aims at highlighting current essential information on the topic. METHODS: Both published and unpublished systematic reviews about lurasidone mono- or adjunctive therapy in the treatment of bipolar depression were searched by two independent authors inquiring PubMed/Cochrane/Embase/Scopus from inception until October 2016...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28539103/possible-oxcarbazepine-inductive-effects-on-aripiprazole-metabolism-a-case-report
#16
Ian R McGrane, Joshua G Loveland, Jose de Leon
Oxcarbazepine is a cytochrome P450 (CYP) 3A4 inducer, which is structurally similar to carbamazepine. Although lacking Food and Drug Administration approval, oxcarbazepine is sometimes prescribed to treat aggressive behavior in youth with autism spectrum disorder (ASD). These youths may also be taking second-generation antipsychotics, some of which are substrates of the CYP3A4 metabolic pathway. The combination of these medications may result in decreased serum antipsychotic concentrations, potentially reducing effectiveness...
January 1, 2017: Journal of Pharmacy Practice
https://www.readbyqxmd.com/read/28499900/lurasidone-in-post-menopausal-females-with-major-depressive-disorder-with-mixed-features-post-hoc-analysis-of-a-placebo-controlled-trial
#17
John Sramek, Antony Loebel, Michael Murphy, Yongcai Mao, Andrei Pikalov, Neal R Cutler
BACKGROUND: Several studies have found that depressed, post-menopausal females may respond differently to antidepressants compared to pre-menopausal females. The atypical antipsychotic lurasidone, whose mechanism of action differs from SSRIs and other standard antidepressants, was shown in a 6-week randomized, flexible-dose, placebo-controlled study (n=209), to be effective in treating major depressive disorder (MDD) with mixed features (subthreshold hypomanic symptoms). This post-hoc analysis assessed the efficacy of lurasidone in this study by menopausal status...
May 9, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/28490709/-research-progress-in-mechanisms-and-clinical-application-for-blonanserin-and-lurasidone-in-improving-cognitive-function-of-schizophrenia
#18
Qi Zheng, Bangshan Liu, Shuyin Xu, Mei Liao, Yan Zhang, Lingjiang Li
Cognition deficit is one of the most common symptoms of schizophrenia, including abstract thinking and memory, and attention deficits. Previous studies have suggested that the improvement of cognition is very important for the recovery of disease and social function for the patients. Recent studies indicated that two new atypical antipsychotics, blonanserin and lurasidone, are expected to improve the cognitive impairment in patients with schizophrenia. This review introduces pathogenesis of cognitive impairment in schizophrenia, mechanisms of blonanserin and lurasidone in the improvement of cognitive impairment and progress in their clinical application for schizophrenia...
April 28, 2017: Zhong Nan da Xue Xue Bao. Yi Xue Ban, Journal of Central South University. Medical Sciences
https://www.readbyqxmd.com/read/28478684/lurasidone-associated-neutropenia
#19
Sarvesh Singh, Hafeez Ahmad, Alexander Panickacheril John
No abstract text is available yet for this article.
May 1, 2017: Australian and New Zealand Journal of Psychiatry
https://www.readbyqxmd.com/read/28475373/efficacy-and-safety-of-lurasidone-in-adolescents-with-schizophrenia-a-6-week-randomized-placebo-controlled-study
#20
Robert Goldman, Antony Loebel, Josephine Cucchiaro, Ling Deng, Robert L Findling
OBJECTIVE: To evaluate the efficacy and safety of lurasidone in acutely symptomatic adolescent patients with schizophrenia. METHODS: Patients aged 13-17 years were randomly assigned to 6 weeks of double-blind, fixed-dose lurasidone (40 or 80 mg/day) or placebo. Primary and key secondary efficacy measures were change from baseline to week 6 in the Positive and Negative Symptom Scale (PANSS) total score and Clinical Global Impressions-Severity (CGI-S) score, respectively, using mixed model for repeated measurement (MMRM) analysis...
August 2017: Journal of Child and Adolescent Psychopharmacology
keyword
keyword
27111
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"